Publications by authors named "Peter Trask"

Claim this Profile
L
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.
Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Dame Lesley Fallowfield, Päivi Auvinen, Peter Trask

Clin Breast Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.
Jiawen Zhu, Amy Schroeder, Sabine Frank, Christophe Boetsch, Candice Jamois, Peter Trask

Clin Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are changes in patient-reported outcomes prognostic for diffuse large B-Cell lymphoma survival? Results from the GOYA trial.
Jessie T Yan, Célia Bel, Peter C Trask, Ernest Lo

J Patient Rep Outcomes· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, Matthew H Taylor, Martin Schuler, Peter Trask

Thyroid· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
Bellinda L King-Kallimanis, Melanie Calvert, David Cella, Kim Cocks, Corneel Coens, Peter Trask

Value Health· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials.
Peter C Trask, Tracy Holt, Timothy Pearman

Qual Life Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis.
Miguel A Canales, Thomas A Buchholz, Jaisson A P Bortolini, Laura M Fogliatto, Takayuki Ishikawa, Peter Trask

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.
Huang Huang, Asim Datye, Ming Fan, Andrea Knapp, Tina Nielsen, Peter C Trask

Cancer Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Michael U Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Peter Trask

Res Pract Thromb Haemost· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Alexey V Danilov, Habte A Yimer, Michael A Boxer, John M Burke, Sunil Babu, Peter C Trask

Clin Lymphoma Myeloma Leuk· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Ian E Krop, Seock-Ah Im, Carlos Barrios, Hervé Bonnefoi, Julie Gralow, Peter Trask

J Clin Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies.
Aric Parnes, Johnny N Mahlangu, Steven W Pipe, Ido Paz-Priel, Michaela Lehle, Peter C Trask

Haemophilia· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen, Peter Trask

Eur J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
Johannes Oldenburg, Huyen Tran, Flora Peyvandi, Ramiro Núñez, Peter Trask

Haemophilia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stephan Stilgenbauer, Francesc Bosch, Osman Ilhan, Jens Kisro, Béatrice Mahé, Peter Trask

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Christine Kempton, Peter Trask, Aric Parnes, Markus Niggli, Avrita Campinha-Bacote

Haemophilia· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
Andrew Davies, Peter Trask, Judit Demeter, Axel Florschütz, Mathias Hänel

Ann Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).
Sylvia von Mackensen, Olivier Catalani, Elina Asikanius, Ido Paz-Priel, Michaela Lehle, Peter Trask

Haemophilia· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.
Maria Elisa Mancuso, Johnny Mahlangu, Robert Sidonio, Peter Trask, Marianne Uguen

Haemophilia· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Johannes Oldenburg, Midori Shima, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Peter Trask

Pediatr Blood Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Rachael Lawrance, Evgeny Degtyarev, Philip Griffiths, Peter Trask, Helen Lau

J Patient Rep Outcomes· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, Eleftherios P Mamounas, Gunter von Minckwitz, Peter Trask

Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, Chiun-Sheng Huang, Nadia Harbeck, Peter Trask

J Clin Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan, Midori Shima, Maria Elisa Mancuso, Peter Trask

Haemophilia· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Johannes Oldenburg, Johnny N Mahlangu, Willem Bujan, Peter Trask, Michael U Callaghan

Haemophilia· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis